Caxton Associates LP Argenx Se Transaction History

Caxton Associates LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $4.32 Million - $5.07 Million	12,000 New	12,000 $4.68 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $289,133 - $339,951	-845 Reduced 54.2%	714 $270,000
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $67,610 - $77,962	-197 Reduced 11.22%	1,559 $550,000
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $473,382 - $665,313	1,756 New	1,756 $665,000
Q4 2021 Feb 14, 2022	SELL	$272.01 - $353.03 $583,461 - $757,249	-2,145 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $402,380 - $478,191	1,364 Added 174.65%	2,145 $648,000
Q2 2021 Aug 16, 2021	BUY	$257.11 - $319.92 $200,802 - $249,857	781 New	781 $235,000
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $251,355 - $312,368	-1,013 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$215.51 - $272.51 $218,311 - $276,052	1,013 New	1,013 $266,000
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $247,106 - $451,244	-1,939 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$108.83 - $165.23 $211,021 - $320,380	1,939 New	1,939 $255,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.